Plain-English translation of NCT07188805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Researchers are testing whether finerenone can help children whose hearts don't pump blood effectively—a condition called left ventricular systolic dysfunction. This medication works by reducing inflammation and scarring in the heart and blood vessels, which may help the heart work better. This is the first study of this medication specifically for children with this type of heart failure.
Children with heart failure that doesn't respond well enough to current treatments need better options. This study is exploring whether this medication could offer additional help by addressing the underlying inflammation and damage that weakens the heart.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the new medication or a placebo (a pill with no medicine) for 3 months, while continuing all your regular heart treatments. You'll visit the study clinic at least 3 times during those 3 months for checkups that include blood pressure and heart rate measurements, heart imaging tests (EKG and ultrasound), blood draws, and physical exams. Doctors will watch closely to make sure the treatment is safe and working well.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States